[Treatment of toxic hepatitis in COVID-19 patients].

Igor Maev R I Shaburov A I Pavlov A I Molodova A G Karakozov S P Kazakov E G Lebedeva A F Ivolgin M N Eremin O B Levchenko

Published in: Terapevticheskii arkhiv (2023)

The use of drugs with hepatoprotective effect in the form of monotherapy in groups 1 (UDCA) and 2 (ademethionine) showed a low therapeutic effect with positive dynamics of clinical and laboratory indicators of toxic hepatitis activity. The use of combined treatment in group 3 (UDCA and ademethionine) demonstrated the maximum therapeutic effect, pronounced positive dynamics in the form of normalization of clinical and laboratory indicators of toxic hepatitis activity.

Keyphrases

combination therapy
clinical trial
open label
drug induced